Pune, India -- (SBWIRE) -- 05/08/2019 -- Our latest research report entitled Monoclonal Antibody Therapeutics Market (by end users (research institute, private clinics, and hospitals), based on source (humanized, human, chimeric), application (cancer, ophthalmological diseases, hematological diseases, infectious diseases, autoimmune diseases)) provides complete and deep insights into the market dynamics and growth of monoclonal antibody therapeutics. Latest information on market risks, industry chain structure monoclonal antibody therapeutics cost structure and opportunities are offered in this report. The past, present and forecast market information will lead to investment feasibility by studying the essential monoclonal antibody therapeutics growth factors. According to the report, the global monoclonal antibody therapeutics market is projected to grow at a CAGR of 12.80% over the forecast period of 2019-2025.

For More Details Get FREE Sample Pages of this Research Report@ https://www.infiniumglobalresearch.com/reports/sample-request/5758

Monoclonal Antibody Therapeutics Market: Insights

A monoclonal antibody therapeutics is a form of immunotherapy that helps in stimulating the patient's immune system and it prevents tumor growth by blocking specific cell receptors. Monoclonal antibodies-based therapeutics is growing with the advent of mammalian cell culture, process, and formulation technology. Monoclonal antibodies are used in the treatment of several major diseases such as cardiovascular and infectious diseases, autoimmune, cancer and inflammation.

Monoclonal Antibody Therapeutics Market: Drivers and Restraints

Growing adoption of monoclonal antibody therapeutics in cancer treatments drives the growth of monoclonal antibody therapeutics market. Monoclonal antibody drugs procure natural immune system to fight cancer. Monoclonal antibodies are beneficial to treat cancer in several ways as it blocks cell growth, flagging cancer cells prevents blood vessel growth and blocks immune system inhibitors. Furthermore, rising use of monoclonal antibodies for the treatment of autoimmune diseases particularly in rheumatoid arthritis and multiple sclerosis boosts the growth of monoclonal antibody therapeutics market. Rapid development in the hybridoma technique and increasing approvals of monoclonal antibodies for the treatment of several diseases contribute to the growth of monoclonal antibody therapeutics market. Increasing prevalence of Alzheimer's disease, cancer, autoimmune diseases and growing awareness regarding several diseases fuels the growth of monoclonal antibody therapeutics market. However, the high cost of monoclonal antibodies may hamper the growth of monoclonal antibody therapeutics market. Moreover, increasing investment in research and development, as well as drug approvals for the treatment of several diseases, provides beneficial opportunities for the monoclonal antibody therapeutics market.

Request a Discount on Standard Prices of this Premium Report @ https://www.infiniumglobalresearch.com/reports/request-discount/5758

Monoclonal Antibody Therapeutics Market: Regional Analysis

Geographically, North America dominated the monoclonal antibody therapeutics market. Approval of monoclonal antibodies by the US FDA, development in healthcare infrastructure, huge expenditure and investment in research and development activities contribute to the growth of monoclonal antibody therapeutics market in the region. According to a recent study by American Cancer Society researchers, at least 42% of newly diagnosed cancers in the US, about 740,000 cases in 2019. The monoclonal antibody therapeutics market in the Asia Pacific region is expected to grow at a moderate rate, owing to increasing population and awareness of several diseases and treatments, as well as increasing healthcare expenditure in the region. According to the world health organization, cancer is the second leading cause of death globally and is estimated to account for 9.6 million death in 2018. Europe accounts for 23.4% of the global cancer cases and 20.3% of cancer deaths.

Monoclonal Antibody Therapeutics Market: Segmentation

The report on global monoclonal antibody therapeutics market covers segments such as end users, based on source, and application. On the basis of end users, the sub-markets include research institute, private clinics, and hospitals. On the basis of based on source, the sub-markets include humanized, human, chimeric, and others. On the basis of application, the sub-markets include cancer, ophthalmological diseases, hematological diseases, infectious diseases, autoimmune diseases, and others.

Browse Detailed TOC and Description of this Exclusive Report@ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-monoclonal-antibody-therapeutics-market

Monoclonal Antibody Therapeutics Market: Competitive Landscape

The report provides profiles of the companies in the market such as Novartis AG, Amgen Inc., AbbVie Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Sanofi, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bayer AG, and GlaxoSmithKline Plc.

Reasons to Buy this Report:

- Comprehensive analysis of global as well as regional markets of the monoclonal antibody therapeutics.

- Complete coverage of all the product type and applications segments to analyze the trends, developments, and forecast of market size up to 2025.

- Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.

- Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.